Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arctic Bioscience AS has a Cash Ratio of 0.00. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Arctic Bioscience AS's Cash Ratio or its related term are showing as below:
During the past 8 years, Arctic Bioscience AS's highest Cash Ratio was 17.94. The lowest was 0.02. And the median was 2.02.
OSL:ABS's Cash Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.93 * Ranked among companies with meaningful Cash Ratio only.
Arctic Bioscience AS (OSL:ABS) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Arctic Bioscience AS Cash Ratio Related Terms
Arctic Bioscience AS Cash Ratio Historical Data
* Premium members only.
The historical data trend for Arctic Bioscience AS's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:ABS vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, Arctic Bioscience AS's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arctic Bioscience AS Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Arctic Bioscience AS's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arctic Bioscience AS (OSL:ABS) has a Cash Ratio of 0.00 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Arctic Bioscience AS and its competitors. Over the past decade, Arctic Bioscience AS's Cash Ratio has ranged from 0.02 to 17.94. According to the industry distribution chart, Arctic Bioscience AS ranks #999999 out of 1382 companies in the Biotechnology industry.
Is Arctic Bioscience AS's Cash Ratio too high?
Arctic Bioscience AS's current Cash Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 17.94. Based on the distribution chart, Arctic Bioscience AS ranks #999999 out of 1382 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arctic Bioscience AS has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arctic Bioscience AS's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arctic Bioscience AS ranks #999999 out of 1382 companies for Cash Ratio. This places Arctic Bioscience AS in the lower half of its industry. The industry median Cash Ratio is 2.93. Historically, Arctic Bioscience AS's own Cash Ratio has ranged from 0.02 to 17.94 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Arctic Bioscience AS and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arctic Bioscience AS's current Cash Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arctic Bioscience AS stock overvalued right now?
Based on GuruFocus' analysis, Arctic Bioscience AS (OSL:ABS) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.34, compared to a current price of kr2.79 — trading 35.7% below its estimated fair value. The current Cash Ratio is 0.00. Arctic Bioscience AS's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Arctic Bioscience AS (OSL:ABS), the current Cash Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arctic Bioscience AS (OSL:ABS) Overvalued in 2026?
Based on GuruFocus' analysis, Arctic Bioscience AS stock appears to be undervalued.
The current stock price of kr2.79 is trading 35.7% below its estimated GF Value™ of kr4.34.
GuruFocus considers Arctic Bioscience AS to be Possible Value Trap.
Key valuation signals for OSL:ABS:
Cash Ratio: 0.00
GF Value™: kr4.34 vs. price of kr2.79 (35.7% below fair value)
No single metric tells the full story. See the OSL:ABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. Geographically, the company operates in Norway, the Americas, Europe, and APAC, with the majority of the revenue derived from the Americas.
58GF Score
Get the complete analysis for OSL:ABS
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:ABS has been successfully added to your 
